279 related articles for article (PubMed ID: 11438662)
1. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis.
Eischen CM; Woo D; Roussel MF; Cleveland JL
Mol Cell Biol; 2001 Aug; 21(15):5063-70. PubMed ID: 11438662
[TBL] [Abstract][Full Text] [Related]
2. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
[TBL] [Abstract][Full Text] [Related]
3. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL.
Maclean KH; Keller UB; Rodriguez-Galindo C; Nilsson JA; Cleveland JL
Mol Cell Biol; 2003 Oct; 23(20):7256-70. PubMed ID: 14517295
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
[TBL] [Abstract][Full Text] [Related]
5. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
Eischen CM; Alt JR; Wang P
Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
[TBL] [Abstract][Full Text] [Related]
6. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
7. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.
Cheung WC; Kim JS; Linden M; Peng L; Van Ness B; Polakiewicz RD; Janz S
J Clin Invest; 2004 Jun; 113(12):1763-73. PubMed ID: 15199411
[TBL] [Abstract][Full Text] [Related]
8. Transgenic overexpression of a dominant negative mutant of FADD that, although counterselected during tumor progression, cooperates in L-myc-induced tumorigenesis.
Hueber AO; Bösser S; Zörnig M
Int J Cancer; 2004 Nov; 112(3):536-40. PubMed ID: 15382083
[TBL] [Abstract][Full Text] [Related]
9. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 and c-Myc, but not bax and p53, are expressed during human medullary thyroid tumorigenesis.
Wang DG; Liu WH; Johnston CF; Sloan JM; Buchanan KD
Am J Pathol; 1998 Jun; 152(6):1407-13. PubMed ID: 9626044
[TBL] [Abstract][Full Text] [Related]
11. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
[TBL] [Abstract][Full Text] [Related]
12. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.
Baudino TA; Maclean KH; Brennan J; Parganas E; Yang C; Aslanian A; Lees JA; Sherr CJ; Roussel MF; Cleveland JL
Mol Cell; 2003 Apr; 11(4):905-14. PubMed ID: 12718877
[TBL] [Abstract][Full Text] [Related]
13. IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.
Vecchio E; Golino G; Pisano A; Albano F; Falcone C; Ceglia S; Iaccino E; Mimmi S; Fiume G; Giurato G; Britti D; Scala G; Quinto I
Cell Death Dis; 2019 Apr; 10(4):320. PubMed ID: 30975981
[TBL] [Abstract][Full Text] [Related]
14. Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma.
Kelly PN; Puthalakath H; Adams JM; Strasser A
Blood; 2007 Jun; 109(11):4907-13. PubMed ID: 17317859
[TBL] [Abstract][Full Text] [Related]
15. Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad.
Frenzel A; Labi V; Chmelewskij W; Ploner C; Geley S; Fiegl H; Tzankov A; Villunger A
Blood; 2010 Feb; 115(5):995-1005. PubMed ID: 19965635
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of apoptosis by c-myc in transgenic hepatocytes and effects of growth factors and nongenotoxic carcinogens.
Christensen JG; Goldsworthy TL; Cattley RC
Mol Carcinog; 1999 Aug; 25(4):273-84. PubMed ID: 10449034
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice.
de La Coste A; Mignon A; Fabre M; Gilbert E; Porteu A; Van Dyke T; Kahn A; Perret C
Cancer Res; 1999 Oct; 59(19):5017-22. PubMed ID: 10519417
[TBL] [Abstract][Full Text] [Related]
18. C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent.
Trudel M; Lanoix J; Barisoni L; Blouin MJ; Desforges M; L'Italien C; D'Agati V
J Exp Med; 1997 Dec; 186(11):1873-84. PubMed ID: 9382886
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia.
Högstrand K; Hejll E; Sander B; Rozell B; Larsson LG; Grandien A
PLoS One; 2012; 7(2):e31366. PubMed ID: 22393362
[TBL] [Abstract][Full Text] [Related]
20. Omomyc expression in skin prevents Myc-induced papillomatosis.
Soucek L; Nasi S; Evan GI
Cell Death Differ; 2004 Sep; 11(9):1038-45. PubMed ID: 15143346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
